Targeted radiopharmaceutical specialist Precirix NV has closed an €80 million (US$87.8 million) series B financing, enabling it to complete phase II development of CAM-H2, a potential treatment for HER2-positive metastatic breast cancer and gastric cancer. The round follows initial data showing there were no dose limiting toxicities in the first cohort of patients in the phase I/II trial, and a positive review from the safety committee.
Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.
Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.
Investors are backing precision medicine company Cancer IQ Inc. with $14 million to expand use of its cancer prevention platform. The series B funds will be used to scale the company’s cancer screening service among diverse, uninsured, and rural populations in the U.S.
LONDON – Epsilogen Ltd. has raised £30.8 million (US$41.5 million) in an oversubscribed series B, after its lead immunoglobulin E (IgE) program delivered positive results in a phase I in advanced solid tumors. The money is to fund a phase Ib trial of the product, Mov18 IgE – the first and only IgE antibody to have made it to the clinic – in platinum-resistant ovarian cancer.
Mindmaze SA continued to add significant funds to its coffers with $105 million as part of a series B financing round, following a $125 million debt financing in October. The new money brings total funding to more than $300 million for the company’s virtual reality-based digital neurotherapeutics platform. Its successful fundraising has pushed the company into unicorn status, making it the first Swiss firm to be valued at more than $1 billion.
Third Harmonic Bio Inc. CEO Natalie Holles said the company’s $105 million in series B money will push THB-001 – a first-in-class, highly selective, oral inhibitor of wild-type KIT – “well past the first proof-of-concept study in inducible urticaria [hives].”
Star Therapeutics Inc. emerged from stealth mode to tell the world about its approach to drug discovery and development in rare diseases, and to spin out Electra Therapeutics Inc., the first in a projected family of companies.
Arkuda Therapeutics Inc., a company targeting lysosomal dysfunction to address neurodegeneration, has completed a $64 million series B financing co-led by Cormorant Asset Management and Pivotal Bioventure Partners. The funds will help advance its lead program, a small-molecule progranulin enhancer for frontotemporal dementia in people with an autosomal dominant mutation in the GRN gene, which codes for the protein.
Leyden Laboratories BV has raised $140 million in a series B financing round to develop drugs that treat whole families of viruses, including a wide-spectrum flu antibody licensed from Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit earlier this month.
RSS
